Jason M. Broderick

The FDA has issued a complete response letter to&nbsp;Spectrum Pharmaceuticals for apaziquone (EOquin; Qapzola) in bladder cancer.&nbsp;<br /> &nbsp;

The FDA has granted a priority review to the multikinase inhibitor midostaurin as a treatment for patients with newly-diagnosed&nbsp;<em>FLT3</em>-mutated acute myeloid leukemia or advanced systemic mastocytosis.

The European Commission has approved the CDK4/6 inhibitor palbociclib as a treatment for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer, either in combination with an aromatase inhibitor in the frontline setting or combined with fulvestrant after progression on endocrine therapy.

The FDA has granted a breakthrough therapy designation to the brentuximab vedotin for the treatment of patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large cell lymphoma following at least 1 prior systemic therapy.&nbsp;<br /> &nbsp;

With olaparib approved and niraparib and rucaparib advancing through clinical development, PARP inhibition is becoming a valuable option in the ovarian cancer armamentarium.

The FDA has approved the PD-1 inhibitor nivolumab as a treatment for patients with metastatic or recurrent squamous cell carcinoma of the head and neck following progression on platinum-based therapy.

The availability of several new treatments has dramatically transformed the treatment paradigm for multiple myeloma in the past few years.

A supplemental new drug application (sNDA) for the use of regorafenib (Stivarga) as a second-line treatment for patients with unresectable hepatocellular carcinoma (HCC) has been submitted to the FDA for approval.

The FDA has granted priority review designation to a new drug application for ribociclib for use in combination with letrozole as a frontline therapy for patients with HR&ndash;positive, HER2-negative advanced breast cancer.

A new drug application for brigatinib for patients with metastatic ALK-positive NSCLC who are resistant to prior crizotinib (Xalkori) has been granted priority review by the FDA.

Updated data from the CheckMate-205 trial demonstrated that nivolumab (Opdivo) had an objective response rate (ORR) of 73% in a cohort of patients with classical Hodgkin lymphoma.

Pegylated liposomal irinotecan (Onivyde) in combination with fluorouracil (5-FU) and leucovorin has been approved by the European Commission (EC) for patients with metastatic pancreatic adenocarcinoma.

Pembrolizumab (Keytruda) has received FDA approval for the frontline treatment of patients with metastatic non&shy;&ndash;small cell lung cancer (NSCLC) whose tumors have &ge;50% PD-L1 expression based on an FDA-approved test and who do not harbor EGFR or ALK aberrations.

The FDA has updated the label for enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC) to include new data from the phase II TERRAIN study, according to the codevelopers of the androgen receptor inhibitor, Astellas and Pfizer.

Findings of the phase III KEYNOTE-045 trial showed pembrolizumab (Keytruda) demonstrated improved survival compared with chemotherapy in previously treated patients with advanced urothelial cancer.

The PDGFR&alpha; antagonist olaratumab (Lartruvo) has been granted an accelerated approval from the FDA&nbsp;in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma (STS) who are not candidates for radiotherapy or surgery.

Atezolizumab has received FDA approval for the treatment of patients with metastatic NSCLC who have progressed after a platinum-containing regimen and an FDA-approved targeted therapy for those patients harboring <em>EGFR</em> or <em>ALK</em> abnormalities.&nbsp;

The positive opinion for the BCL-2 inhibitor has been sent to the European Commission, which usually issues its final approval decision within 2 to 3 months of the CHMP recommendation.

Results from the KRISTINE^&nbsp;and NSABP B-41&nbsp;trials provided the latest data on the use of pertuzumab, trastuzumab, ado-trastuzumab emtansine, and lapatinib for the neoadjuvant treatment of patients with HER2-positive breast cancer.

Cabozantinib (Cabometyx) reduced the risk of progression or death by 31% compared with sunitinib (Sutent) in the frontline setting for patients with metastatic renal cell carcinoma (RCC).

Atezolizumab (Tecentriq) reduced the risk of death by 27% compared with docetaxel in patients with advanced non&ndash;small cell lung cancer (NSCLC) following the failure of platinum-based chemotherapy.

Updated findings from the phase III EORTC 18071 trial show treatment with ipilimumab (Yervoy) reduced the risk of death by 28% versus placebo in patients with high-risk stage III melanoma.&nbsp;

Over one-fourth of patients with metastatic melanoma in Europe do not have access to groundbreaking therapies that could extend their lives, according to a survey presented at the 2016 ESMO Congress.

In a 14-0 vote, the FDA&rsquo;s Oncologic Drugs Advisory Committee (ODAC) denied the approval of apaziquone (EOquin; Qapzola) for intravesical instillation immediately following transurethral resection in patients with non-muscle invasive bladder cancer.

A type II variation application for the use of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma (mUC) who have progressed following platinum-based chemotherapy is now under formal review.

Jennifer Woyach, MD, offers her expert insight into the practical clinical use of CLL treatments.

Findings from a recent phase II trial¹showed that combining&nbsp;the diabetes drug metformin with everolimus (Afinitor) and letrozole resulted in a clinical benefit rate (CBR) of 60% in women with advanced or recurrent endometrioid endometrial cancer.

According to results from the phase III ASCEND-4 trial, ceritinib (Zykadia) improved progression-free survival (PFS) compared with standard chemotherapy as a first-line treatment for patients with <em>ALK</em>-positive non&ndash;small cell lung cancer (NSCLC)

Bruce Cheson, MD,&nbsp;outlines the treatment choices for each of the 3 patient categories of CLL, noting that, regardless of the treatment, &ldquo;a clinical trial is always the preferred option.&rdquo;

The PDGFR&alpha; antagonist olaratumab has been recommended approval by&nbsp;The Committee for Medicinal Products for Human Use (CHMP)&nbsp;for use in combination with doxorubicin for patients with advanced soft tissue sarcoma (STS) who are not good candidates for radiotherapy or surgery.